Skip to Content

Gilteritinib Disease Interactions

There are 2 disease interactions with gilteritinib:


Gilteritinib (applies to gilteritinib) hepatic/renal

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

The effect of severe hepatic (Child-Pugh Class C) or severe renal impairment (Clcr = 29 mL/min) on gilteritinib pharmacokinetics is unknown.


Gilteritinib (applies to gilteritinib) QT interval prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome, Hypokalemia, Magnesium Imbalance

Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval). Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce the dosage of gilteritinib in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during treatment administration.

Gilteritinib drug interactions

There are 438 drug interactions with gilteritinib

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.